Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study
Clinical trial NCT02145143 · COMPLETED
Trial details
- NCT number
- NCT02145143
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Status
- COMPLETED
- Phase
- Early Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2014-05-20
- Primary completion
- 2024-11-21
- Enrollment
- 12
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.